HCMC – Polpharma, a renowned Polish pharmaceutical manufacturer known for its anti-infectives, pain management, and cardiology medicines, has unveiled a strategic collaboration with DKSH to introduce its pharmaceuticals to Vietnam.
In this partnership, Polpharma will leverage DKSH’s extensive local expertise and well-established distribution network to extend its reach to a broader Vietnamese audience. The collaboration focuses on vital therapy areas, including cardiology, gastroenterology, and neurology.
This initiative marks DKSH’s eighth significant healthcare partnership in Vietnam for the year, reinforcing its position as a leader in providing healthcare solutions.
Bernardo Reiner, head of B2B at Polpharma and general manager of Farmaprojects, said that with DKSH’s capabilities and local insights, the company will successfully achieve its business objectives and contribute to the growth of Vietnam’s healthcare market.
Phillip Wray, general director of DKSH Pharma Vietnam, stated, “We harness our world-class services and local insights to drive success for Polpharma.”
This collaboration aims to offer access to European-quality pharmaceutical products from Polpharma, as DKSH continues its mission to enhance the quality of life for the people of Vietnam.
Polpharma, with over 80 years of experience and a presence in 40 markets, produces a staggering 400 million medicine packages annually. Meanwhile, DKSH, operating in 37 markets with a workforce of over 32,000, reported net sales of CHF11.3 billion in 2022.
